Company: PFSA
Filing Date: 2025-09-17
Form Type: S-1/A
Source: 0001213900-25-088333
Chunk: 194

Company: Profusa, Inc.
Filing Date: 2025-09-17
Form: S-1/A
Chunk 194
---
 |                                                |
| Ben C. Hwang, Ph.D.               |     |  57 |     | Chairman of the Board; Chief Executive Officer |
| Fred Knechtel                     |     |  64 |     | Chief Financial Officer                        |
| Rajesh Asorpota                   |     |  56 |     | Director                                       |
| Lauren Chung                      |     |  48 |     | Director                                       |
| Peter O’Rourke                    |     |  52 |     | Lead Independent Director                      |
| Jack Stover                       |     |  71 |     | Director                                       |

The following is information about the experience and attributes of the members of our board of directors and senior executive officers as of the date of this prospectus. The experience and attributes of our directors discussed below provide the reasons that these individuals were selected for board membership, as well as why they continue to serve in such positions. Ben C. Hwang, Ph.D.— Dr. Hwang has served as Profusa’s Chairman of the Board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins University. We believe that Dr. Hwang is well -qualifiedto serve as a director of our company based on his familiarity with Profusa’s business, his experience in the life science industry, and his educational background. Fred Knechtel— Fred Knechtel has served as our Chief Financial Officer and director since July 2025. From August 2022 to August 2023, Mr. Knechtel served as chief financial officer of DiamiR Biosciences. From January 2020 to January 2021, Mr. Knechtel served as chief financial officer of Interpace Biosciences, Inc. From June 2018 to December 2018, Mr. Knechtel served as chief financial officer of GENEWIZ, Inc. From November 2014 to November 2017, Mr. Knechtel served as group chief financial officer of Sims Metal Management. From November 2009 to October 2014, Mr. K